Numbers that tell the tale….

By linking academia with industry and financial partners, and through its special relationship with IRIC, IRICoR has been innovating for nearly 15 years in the way it transforms drug discoveries into therapies for the benefit of patients.
IRICoR is proud to have collaborated on the XTRA La Presse+ edition – Montreal: a hub of health and innovation.
Through an interview with Elizabeth […]

Great partnerships create great opportunities!

The new issue of BIOTECanada’s Insights magazine is now available. IRICoR is proud to have collaborated on this edition. Find an article in Q&A format with IRICoR partner, Ipsen, highlighting the importance of collaboration in life sciences to optimize research and to effectively integrate innovations into the health system.
To read the full article, click

2023 BIO International Convention

IRICoR announces its participation in the BIO 2023 international convention to be held from June 5 to 8, 2023 in Boston. This industry event aims to create business opportunities among life science players from all over the world. It is also an opportunity for companies and institutions to develop partnerships of interest with complementary organizations, in particular through the presentation […]


Montreal, February 27, 2023 – The members of IRICoR’s Board of Directors are proud today to announce the appointment of Elizabeth Douville, Ph.D., ICD.D, to the position of President and Chief Executive Officer of the organization. This appointment comes after Dr. Nadine Beauger, Ph.D., MBA, informed the members of the Board of Directors of her decision to leave the position […]

Ipsen, UdeM and IRICoR broaden existing oncology partnership, with an exclusive license agreement and two new discovery-stage programs

PARIS, FRANCE, MONTREAL, CANADA 15 February 2023 – Ipsen (Euronext: IPN; ADR: IPSEY), Université de Montréal and IRICoR announce that Ipsen has exercised its option to acquire exclusive rights to a pre-clinical stage program with potential oncology applications. This license agreement is the result of a fruitful collaboration established between Ipsen, Université de Montréal and IRICoR in May 2020. Ipsen […]

New Strategic Investment of IRICoR in RejuvenRx Spin-off

MONTRÉAL, January XX, 2023 – RejuvenRx Inc., an emerging biotechnology company developing novel small molecules-based targeted therapies focusing on stem cell biology, announced today a strategic investment from IRICoR, one of its co-founders.
IRICoR, a Centre of Excellence in Commercialization and Research with a focus on drug discovery, co-founded RejuvenRx alongside ExCellThera and its shareholders. This new financial investment in RejuvenRx […]

Dre Gwenaëlle Gavory joins the IRICoR team

IRICoR is very pleased to announce the appointment of Gwenaëlle Gavory, as Scientific Liaison Agent. In this role, Dre Gavory will be in charge of the scientific management and progress of portfolio projects in close collaboration with the VP – Scientific operations.
Before joining IRICoR, Gwenaëlle was administrative project manager at the Institute for Research in Immunology and Cancer of the […]

Intellectual property management: a formidable marketing lever for anticancer therapies

With its concerted approach and its expertise in intellectual property (IP), IRICoR plays a leading role in the marketing of therapeutic solutions resulting from cutting-edge research. For the greatest benefit of patients, here and abroad.
Read the article Le Devoir (only in French)

New VP – Scientific Operations at IRICoR

IRICoR is very pleased to announce the appointment as of September 21, 2022 of Dr. Mario Callejo as Vice-President, Scientific Operations and new member of IRICoR’s Management team.
Dr. Callejo’s main responsibilities consist of supervising activities related to scientific affairs, such as leading and ensuring the preliminary scientific evaluation of potential projects, planning, developing and implementing a balanced portfolio strategy and making investment […]

IRICoR welcomes the appointment of Nadine Beauger as a member of the Board of Directors of Canada’s Stem Cell Network

IRICoR is therefore pleased to announce the appointment of its President and CEO, Ms. Nadine Beauger, to the Board of Directors of Canada’s Stem Cell Network (SCN).
SCN’s Board of Directors provides oversight for strategic planning, annual budgets, performance management and risk mitigation. It is also responsible for confirming the research funding recommendations of SCN’s Research Management Committee and ensuring due […]

« Previous Page | Next Page »

© 2008-2024 IRICoR